However, although ATP-competitive BRAF (V600E) kinase inhibitor such as Vem or its combination with a MEK inhibitor has dramatically improved the treatment outcome for patients with metastatic melanoma (Spain et al., 2016; Simeone et al., 2017; Trojaniello et al., 2019), over 50% of patients develop acquired drug resistance and began to show signs of tumor recurrence within 6–9 months of treatment (Torres-Collado et al., 2018). This evidence concerns the gene MAP2K7 and neoplasm.